Published on
May 29, 2024
- 12:57 GMT
EuMentis Therapeutics’ CMO Randall Marshall to Present on its novel PDE10A inhibitor for Tourette Syndrome at TicCon24
Dr. Marshall's Presentation on Friday May 31, 2024 NEWTON, MA, UNITED STATES, May 29, 2024 /EINPresswire.com/ -- EuMentis Therapeutics, Inc., a clinical stage drug development company focused on the development and commercialization of circuit …
Distribution channels:
Banking, Finance & Investment Industry, Companies
...
